Toxicity of pyroglutaminated amyloid β-peptides 3(pE)-40 and -42 is similar to that of Aβ1 -40 and -42

Journal of Neurochemistry

Volumn 73, Issue 4, 1999, Pages 1584-1589

  Tekirian, T L ^a,b,d   Yang, A Y ^c,e   Glabe, C ^c   Geddes, J W ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; Circular dichroism; Neurotoxins; Peptide fragments

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CEREBROVASCULAR DISEASE; CIRCULAR DICHROISM; CONTROLLED STUDY; FETUS; HIPPOCAMPUS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN POLYMORPHISM; RAT; SENILE PLAQUE;

AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; CEREBRAL CORTEX; CIRCULAR DICHROISM; DOSE-RESPONSE RELATIONSHIP, DRUG; FETUS; HIPPOCAMPUS; MOLECULAR SEQUENCE DATA; NEURONS; NEUROTOXINS; PEPTIDE FRAGMENTS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032863554     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.0731584.x     Document Type: Article

References (22)

1. Brewer G. J., Torricelli J. R., Evege E. K., and Price P. J. (1993) Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J. Neurosci. Res. 35, 567-576.
2. Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C., and Glabe C. (1992) Assembly and aggregation properties of synthetic Alzheimer' s A4/beta amyloid peptide analogs. J. Biol Chem. 267, 546-554.
3. Checler F. (1995) Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease. J. Neurochem. 65, 1431-1444.
4. Harris M. E., Hensley K., Butterfield D. A., Leedle R. A., and Carney J. M. (1995) Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131, 193-202.
5. Hewlett D. R., Jennings K. H., Lee D. C., Clark M. S., Brown F., Wetzel R., Wood S. J., Camilleri P., and Roberts G. W. (1995) Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 4, 23-32.
6. Jiang H., Burdick D., Glabe C. G., Cotman C. W., and Tenner A. J. (1994) Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152, 5050-5059.
7. Kalaria R. N. (1996) Cerebral vessels in ageing and Alzheimer's disease. Pharmacol. Ther. 72, 193-214.
8. Kuda T., Shoji M., Arai H., Kawashima S., and Saido T. C. (1997) Reduction of plasma glutamyl aminopeptidase activity in sporadic Alzheimer's disease. Biochem. Biophys. Res. Commun. 231, 526-530.
9. McDonald J. K. and Barret A. J. (1986) Mammalian Proteases. Academic Press, London.
10. Mills J. and Reiner P. B. (1999) Regulation of amyloid precursor protein cleavage. J. Neurochem. 72, 443-460.
11. Mori H., Takio K., Ogawara M., and Selkoe D. J. (1992) Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J. Biol Chem. 267, 17082-17086.
12. Pike C. J., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1991) In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311-314.
13. Pike C. J., Burdick D., Walencewicz A. J., Glabe C. G., and Cotman C. W. (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676-1687.
14. Pike C. J., Overman M. J., and Cotman C. W. (1995a) Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J. Biol. Chem. 270, 23895-23898.
15. Pike C. J., Walencewicz-Wasserman A. J., Kosmoski J., Cribbs D. H., Glabe C. G., and Cotman C. W. (1995b) Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem. 64, 253-265.
16. Russo C., Saido T. C., DeBusk L. M., Tabaton M., Gambetti P., and Teller J. K. (1997) Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett. 409, 411-416.
17. Saido T. C. (1998) Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol. Aging 19, S69-S75.
18. Saldo T. C., Iwatsubo T., Mann D. M., Shimada H., Ihara Y., and Kawashima S. (1995) Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 14, 457-466.
19. Saido T. C., Yamao-Harigaya W., Iwatsubo T., and Kawashima S. (1996) Amino-and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci. Lett. 215, 173-176.
20. Selkoe D. J. (1989) Amyloid beta protein precursor and the pathogenesis of Alzheimer's disease. Cell 58, 611-612.
21. Simmons L. K., May P. C., Tomaselli K. J., Rydel R. E., Fuson K. S., Brigham E. F., Wright S., Lieberburg I., Becker G. W., Brems D. N., and Li W. Y. (1994) Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol. Pharmacol. 45, 373-379.
22. Tekirian T. L., Saido T. C., Markesbery W. R., Russell M. J., Wekstein D. R., Patel E., and Geddes J. W. (1998) N-Terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J. Neuropathol. Exp. Neurol. 57, 76-94.